# Summit Therapeutics Inc.: financial statements, quarterly

SMMT · Nasdaq · CIK 1599298 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/smmt.md) · [Financials](/companies/smmt/financials.md) · [Filings](/companies/smmt/filings.md) · [Insiders](/companies/smmt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/smmt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001599298-24-000158.md) | [0.0 d](/filings/0001599298-25-000048.md) | not reported | not reported | [0.0](/filings/0001599298-24-000158.md) | [0.0 d](/filings/0001599298-25-000048.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [15.3](/filings/0001599298-23-000098.md) | [24.8 d](/filings/0001599298-24-000031.md) | [30.9](/filings/0001599298-24-000085.md) | not reported | not reported | not reported | [51.3](/filings/0001599298-26-000039.md) | [208](/filings/0001599298-26-000068.md) | not reported | not reported | [133](/filings/0001599298-26-000039.md) | [158](/filings/0001599298-26-000068.md) |
| Operating income | $m | [(20.5)](/filings/0001599298-24-000158.md) | [(36.2) d](/filings/0001599298-25-000048.md) | [(42.4)](/filings/0001599298-24-000085.md) | [(59.6)](/filings/0001599298-24-000117.md) | [(58.4)](/filings/0001599298-24-000158.md) | [(65.6) d](/filings/0001599298-25-000048.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | not reported | not reported | [3.1](/filings/0001599298-25-000089.md) | [3.1](/filings/0001599298-25-000126.md) | [2.5](/filings/0001599298-25-000159.md) | [0.0 d](/filings/0001599298-26-000015.md) | [0.0](/filings/0001599298-25-000089.md) | [0.0](/filings/0001599298-25-000126.md) | [0.0](/filings/0001599298-25-000159.md) | [0.0 d](/filings/0001599298-26-000015.md) | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(21.3)](/filings/0001599298-24-000158.md) | [(36.6) d](/filings/0001599298-26-000015.md) | [(43.5)](/filings/0001599298-25-000159.md) | [(60.4)](/filings/0001599298-25-000159.md) | [(56.3)](/filings/0001599298-25-000159.md) | [(61.2) d](/filings/0001599298-26-000015.md) | [(62.9)](/filings/0001599298-26-000068.md) | [(566)](/filings/0001599298-26-000068.md) | [(232)](/filings/0001599298-25-000159.md) | [(219) d](/filings/0001599298-26-000015.md) | [(189)](/filings/0001599298-26-000068.md) | [(216)](/filings/0001599298-26-000068.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0001599298-24-000158.md) | not reported | [(0.06)](/filings/0001599298-25-000089.md) | [(0.09)](/filings/0001599298-25-000126.md) | [(0.08)](/filings/0001599298-25-000159.md) | not reported | [(0.09)](/filings/0001599298-26-000039.md) | [(0.76)](/filings/0001599298-26-000068.md) | [(0.31)](/filings/0001599298-25-000159.md) | not reported | [(0.24)](/filings/0001599298-26-000039.md) | [(0.28)](/filings/0001599298-26-000068.md) |
| Basic EPS | $ per share | [(0.03)](/filings/0001599298-24-000158.md) | not reported | [(0.06)](/filings/0001599298-25-000089.md) | [(0.09)](/filings/0001599298-25-000126.md) | [(0.08)](/filings/0001599298-25-000159.md) | not reported | [(0.09)](/filings/0001599298-26-000039.md) | [(0.76)](/filings/0001599298-26-000068.md) | [(0.31)](/filings/0001599298-25-000159.md) | not reported | [(0.24)](/filings/0001599298-26-000039.md) | [(0.28)](/filings/0001599298-26-000068.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [23.8](/filings/0001599298-23-000098.md) | [71.4](/filings/0001599298-26-000015.md) | [61.3](/filings/0001599298-25-000089.md) | [28.4](/filings/0001599298-25-000126.md) | [93.8](/filings/0001599298-25-000159.md) | [105](/filings/0001599298-26-000015.md) | [212](/filings/0001599298-26-000039.md) | [298](/filings/0001599298-26-000068.md) | [239](/filings/0001599298-25-000159.md) | [225](/filings/0001599298-26-000068.md) | [107](/filings/0001599298-26-000039.md) | [419](/filings/0001599298-26-000068.md) |
| Current assets | $m | [205](/filings/0001599298-23-000098.md) | [190](/filings/0001599298-25-000048.md) | [163](/filings/0001599298-24-000085.md) | [329](/filings/0001599298-24-000117.md) | [490](/filings/0001599298-24-000158.md) | [424](/filings/0001599298-26-000015.md) | [371](/filings/0001599298-25-000089.md) | [309](/filings/0001599298-25-000126.md) | [246](/filings/0001599298-25-000159.md) | [720](/filings/0001599298-26-000068.md) | [617](/filings/0001599298-26-000039.md) | [721](/filings/0001599298-26-000068.md) |
| Total assets | $m | [218](/filings/0001599298-23-000098.md) | [203](/filings/0001599298-25-000048.md) | [177](/filings/0001599298-24-000085.md) | [342](/filings/0001599298-24-000117.md) | [503](/filings/0001599298-24-000158.md) | [436](/filings/0001599298-26-000015.md) | [384](/filings/0001599298-25-000089.md) | [324](/filings/0001599298-25-000126.md) | [262](/filings/0001599298-25-000159.md) | [751](/filings/0001599298-26-000068.md) | [648](/filings/0001599298-26-000039.md) | [752](/filings/0001599298-26-000068.md) |
| Current liabilities | $m | [114](/filings/0001599298-23-000098.md) | [20.4](/filings/0001599298-25-000048.md) | [23.4](/filings/0001599298-24-000085.md) | [140](/filings/0001599298-24-000117.md) | [59.0](/filings/0001599298-24-000158.md) | [41.7](/filings/0001599298-26-000015.md) | [34.9](/filings/0001599298-25-000089.md) | [60.3](/filings/0001599298-25-000126.md) | [64.9](/filings/0001599298-25-000159.md) | [73.0](/filings/0001599298-26-000068.md) | [83.3](/filings/0001599298-26-000039.md) | [104](/filings/0001599298-26-000068.md) |
| Total liabilities | $m | [119](/filings/0001599298-23-000098.md) | [125](/filings/0001599298-25-000048.md) | [133](/filings/0001599298-24-000085.md) | [147](/filings/0001599298-24-000117.md) | [64.9](/filings/0001599298-24-000158.md) | [46.8](/filings/0001599298-26-000015.md) | [39.5](/filings/0001599298-25-000089.md) | [64.6](/filings/0001599298-25-000126.md) | [69.5](/filings/0001599298-25-000159.md) | [92.3](/filings/0001599298-26-000068.md) | [102](/filings/0001599298-26-000039.md) | [122](/filings/0001599298-26-000068.md) |
| Shareholders' equity | $m | [99.4](/filings/0001599298-24-000158.md) | [77.7](/filings/0001599298-26-000015.md) | [44.2](/filings/0001599298-25-000159.md) | [195](/filings/0001599298-25-000159.md) | [438](/filings/0001599298-25-000159.md) | [389](/filings/0001599298-26-000068.md) | [344](/filings/0001599298-26-000068.md) | [259](/filings/0001599298-26-000068.md) | [192](/filings/0001599298-25-000159.md) | [659](/filings/0001599298-26-000068.md) | [546](/filings/0001599298-26-000068.md) | [630](/filings/0001599298-26-000068.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(14.9) d](/filings/0001599298-24-000158.md) | [(19.5) d](/filings/0001599298-26-000015.md) | [(30.1)](/filings/0001599298-25-000089.md) | [(33.0) d](/filings/0001599298-25-000126.md) | [(30.3) d](/filings/0001599298-25-000159.md) | [(48.7) d](/filings/0001599298-26-000015.md) | [(61.2)](/filings/0001599298-26-000039.md) | [(66.7) d](/filings/0001599298-26-000068.md) | [(93.1) d](/filings/0001599298-25-000159.md) | [(102) d](/filings/0001599298-26-000015.md) | [(122)](/filings/0001599298-26-000039.md) | [(141) d](/filings/0001599298-26-000068.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001599298-24-000158.md) | [0.0 d](/filings/0001599298-26-000015.md) | [0.0](/filings/0001599298-25-000089.md) | [0.1 d](/filings/0001599298-25-000126.md) | [0.1 d](/filings/0001599298-25-000159.md) | [0.0 d](/filings/0001599298-26-000015.md) | [0.4](/filings/0001599298-26-000039.md) | [0.0 d](/filings/0001599298-26-000068.md) | [0.1 d](/filings/0001599298-25-000159.md) | [0.2 d](/filings/0001599298-26-000015.md) | [0.2](/filings/0001599298-26-000039.md) | [0.9 d](/filings/0001599298-26-000068.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [209](/filings/0001599298-23-000098.md) | [378](/filings/0001599298-24-000085.md) | [698](/filings/0001599298-24-000117.md) | [698](/filings/0001599298-24-000158.md) | [702](/filings/0001599298-25-000089.md) | [708](/filings/0001599298-25-000126.md) | [727](/filings/0001599298-25-000159.md) | [738](/filings/0001599298-26-000039.md) | [743](/filings/0001599298-26-000068.md) | [743](/filings/0001599298-25-000159.md) | [775](/filings/0001599298-26-000039.md) | [778](/filings/0001599298-26-000068.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 797,749,602 at 2026-07-17, from the cover of the [10-Q filed 2026-07-23](/filings/0001599298-26-000068.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.